Clinical Trial

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-04-06; most recent amendment 2025-03-10.
Trial Details
NCT Number NCT05325645
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Collaborators: Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Acute Schizophrenia
Enrollment 450 participants
Start Date 2022-07-21
Primary Completion 2026-02 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-03-12